

OSE Publications

2017

Han L, **Ball R, Pamer CA**, Altman RB, Proestel S. Development of an Automated Assessment Tool for MedWatch Reports in the FDA Adverse Event Reporting System. In press, J Am Med Inform Assoc.

Sandhu SK, Hua W, MaCurdy TE, Franks RL, Avagyan A, Kelman J, Worrall CM, **Ball R, Nguyen M**. Near real-time surveillance for Guillain-Barré Syndrome after Influenza Vaccination among the Medicare Population, 2010-11 to 2013-14. In press, Vaccine.

By K, **McAninch JK**, Keeton SL, **Secora A, Kornegay CJ**, Hwang CS, Ly T, Levenson MS. Important Statistical Considerations in the Evaluation of Post-market Studies to Assess Whether Opioids With Abuse-Deterrent Properties Result in Reduced Abuse In the Community. *Pharmacoepidemiology and Drug Safety*. 2017 Aug 23. DOI: 10.1002/pds.4287.

Zhu Y, **Coyle DT, Mohamoud M, Zhou E, Eworuke E, Dormitzer C, Staffa J**. Concomitant use of buprenorphine for medication-assisted treatment of opioid use disorder and benzodiazepines: Using the Prescription Behavior Surveillance System. International Conference on Pharmacoepidemiology; August 2017, Montreal, Canada. Oral presentation. Accepted.

Sewell CA, Chang CY, **Chehab MM**, Nguyen CP. Domperidone for Lactation: What Health Care Providers Need to Know. *Obstet Gynecol*. June 2017;129:1-6. DOI: 10.1097/AOG.0000000000002033 [Epub ahead of print – 2017 May 5].

Taylor LG, Bird ST, Sahin L, Tassinari M, Green P, Reichman M, et al. Antiemetic use among pregnant women in the United States: the escalating use of ondansetron. *Pharmacoepidemiol Drug Saf*. 2017 May;26(5):592-596. doi: 10.1002/pds.4185. Epub 2017 Feb 21.

Kesselheim AS, Donneyong M, **Dal Pan GJ, Zhou EH**, Avorn J, Schneeweiss S, Seeger JD, Changes in prescribing and healthcare resource utilization after FDA Drug Safety Communications involving zolpidem-containing medications. *Pharmacoepidemiol Drug Saf*. 2017 Apr 27. doi: 10.1002/pds.4215.

Bersoff-Matcha SJ, Cao K, Jason M, Ajao A, Jones SC, Meyer T, Brinker A. Hepatitis B Reactivation Associated with Direct-Acting Antiviral Therapy for Chronic Hepatitis C: A Review of Cases Reported to the U.S. Food and Drug Administration Adverse Event Reporting System. *Ann Intern Med*. 2017 Apr 25. doi: 10.7326/M17-0377.

Graham CS. Making Do With What We Have. *Ann Intern Med*. 2017 Apr 25. doi: 10.7326/M17-0907.

Nevo ON, Brinker AD, Diak IL. Postmarketing Safety Review of Aripiprazole and Impulse Control Problems. April 24, 2017. College of Psychiatric and Neurologic Pharmacists. Phoenix, AZ. Poster #370.

Woronow D, Swank K, Wu E, Kortepeter C, Levin RL. Labeling and Drug Safety Communication Approaches to Loperamide Abuse. *JACC: Clinical Electrophysiology*. 2017 April vol. 3, issue 4. DOI: 10.1016/j.jacep.2017.02.011

Swank, K, Wu E, Kortepeter C, McAninch J, Levin RL. Adverse Event Detection using the FDA Post-marketing Drug Safety Surveillance System: Cardiotoxicity associated with Loperamide Abuse and

Misuse. J Am Pharm Assoc (2003). 2017 Mar - Apr; 57(2S):S63-S67. doi: 10.1016/j.japh.2016.11.011. Epub 2017 Jan 7

Pham, T, Major, JM, Chai, G, Moeny, D, Wang, C, Blum, MD. Response to Consumer Healthcare Products Association letter to “Trend in rates of acetaminophen-related adverse events in the United States”. *Pharmacoepidemiol Drug Saf.* 2017 Mar;26(3):355. doi: 10.1002/pds.4172

Woloshin S, Schwartz LM, Dejene S, Rausch P, **Dal Pan GJ, Zhou EH,** Kesselheim AS. Media coverage of FDA Drug Safety Communications about zolpidem: A quantitative and qualitative analysis. *Journal of Health Communication.* 2017 Mar 24:1-8.

Zhou EH, Seymour S, Goulding MR, Kang EM, Major JM, and Iyasu S. The US Food and Drug Administration’s drug safety recommendations and long-acting beta2-agonist dispensing pattern changes in adult asthma patients: 2003–2012. *Asthma Allergy.* 2017 Mar 16;10:67-74.

Zhu Y, **Liu W,** Li Y, Wang X, Winterstein AG. Prevalence of ADHD in Publicly Insured Adults. *J Atten Disord.* 2017 Mar 1:1087054717698815. doi: 10.1177/1087054717698815.

Kesselheim AS, McGraw SA, Dejene SZ, Rausch P, **Dal Pan GJ,** Lappin BM, **Zhou EH,** Avorn J, Campbell EG. Patient and Physician Perceptions of Drug Safety Information for Sleep Aids: A Qualitative Study. *Drug Saf.* 2017 Feb 28. doi: 10.1007/s40264-017-0516-3.

Taylor LG, Bird ST, Sahin L, Tassinari MS, **Greene P,** Reichman ME, Andrade SE, Haffner K, Toh S. Antiemetic use among pregnant women in the United States: the escalating use of ondansetron. *Pharmacoepidemiol Drug Saf.* 2017 Feb 21. doi: 10.1002/pds.4185.

Hampp, C, Pippins J. Pioglitazone and bladder cancer: FDA’s assessment. *Pharmacoepidemiology and Drug Safety.* 2017 Feb; 26:117-118.

Gelperin K, Hammad H, **Leishear K, Bird ST, Taylor L, Hampp C,** Sahin L. A Systematic Review of Pregnancy Exposure Registries: Examination of Protocol-specified Pregnancy Outcomes, Target Sample Size, and Comparator Selection. *Pharmacoepidemiol Drug Saf.* 2017 Feb; 26:208-214.

Eworuke E. Can left truncation of the data explain the observed null associations? *J Allergy Clin Immunol Pract.* 2017 Jan - Feb;5(1):213. doi: 10.1016/j.jaip.2016.08.020. Epub 2016 Nov 1.

Chehab M, Mohamoud M, Gada N, Proestel S, Chai C, Moeny D.

Unapproved Domperidone Use and Cardiac Adverse Events: Data From The FDA Adverse Event Reporting System And US Drug Utilization. Federal Pharmacy Seminar 2016 Abstracts of Contributed Papers . *JAPhA.* Jan-Feb 2017; 57(1):e1-e17. DOI: <http://dx.doi.org/10.1016/j.japh.2016.12.004> [Epub]

Miguel A, Hall A, **Liu W,** Garrett J, Ballew A, Yang TH, Segal R. Improving Comprehensive Medication Review Acceptance by Using a Standardized Recruitment Script: A Randomized Control Trial. *J Manag Care Spec Pharm.* 2017 Jan;23(1):13-21.

Nevo ON, Brinker AD, Diak IL, Kortepeter CM. Response to: Improvement of sleep architecture parameters in cirrhotic patients with recurrent hepatic encephalopathy with the use of rifaximin: hepatic encephalopathy in association with zolpidem. *European Journal of Gastroenterology & Hepatology.* *Accepted, Pending publication.*

Eworuke E., Popat V., **Moeny D.** Bone Mineral Density Testing and Bisphosphonate and Estrogen Prescribing Associated with Depot Medroxyprogesterone Acetate (DMPA) Utilization – The impact of the Boxed Warning. *Journal of Clinical Pharmacy and Therapeutics* 2017. *Accepted, Pending publication.*

Eworuke E., Lee JY, Soule L., Popat. V, **Moeny D.** The impact of the boxed warning on the duration of use of Depot Medroxyprogesterone Acetate. *Pharmacoepidemiology and Drug Safety* 2017. *Accepted, Pending Publication.*

Sorbello A, Ripple A, Tinning J, **Munoz M**, Hasan R, Ly T, Francis H, Bodenreider. Harnessing scientific literature reports for pharmacovigilance: Prototype software analytical tool with usability feedback. *Accepted, Pending Publication.*

Munoz M, Kulick C, Kortepeter C, Levin R, Avigan M. Liver Injury Associated with Dimethyl Fumarate in Multiple Sclerosis Patients. *Multiple Sclerosis Journal.* *Accepted, Pending Publication.*

Rider, B., Mehta, H., Merchant, L. Special considerations for proprietary name review: focus on prescription products commonly prescribed “as directed”. *BMJ Quality & Safety, Pending Acceptance.*

Chi-Ming T, Pham T. Use of proprietary names by prescribers when prescribing over-the-counter (OTC) drug products. (*Pending Submission*)

2016

Sherman RE, Anderson SA, **Dal Pan GJ**, Gray GW, Gross T, Hunter NL, LaVange L, Marinac-Dabic D, Marks PW, Robb MA, Shuren J, Temple R, Woodcock J, Yue LQ, Califf RM. Real-World Evidence - What Is It and What Can It Tell Us? *N Engl J Med.* 2016 Dec 8;375(23):2293-2297.

Secora A, Trinidad JP, Zhang R, **Gill R, Dal Pan G.** Drug availability adjustments in population-based studies of prescription opioid abuse. *Pharmacoepidemiol Drug Saf.* 2016 Dec 21. doi: 10.1002/pds.4139. [Epub ahead of print]

Trinidad J, Warner M, Bastian B, et al. Using literal text from the death certificate to enhance mortality statistics: Characterizing drug involvement in deaths. *National Vital Statistics Reports;* 2016, Dec 20; vol 65 no 9. Hyattsville, MD: National Center for Health Statistics.

Warner M, **Trinidad JP,** Bastian BA, et al. Drugs most frequently involved in drug overdose deaths: United States, 2010–2014. *National Vital Statistics Reports;* 2015, Dec 20; vol 65 no 10. Hyattsville, MD: National Center for Health Statistics.

Munoz MA, Tinning JM, **Brinker AD,** Gatti JC, **Avigan M.** Data mining of FDA's Adverse Events Reporting System Database to Evaluate Drug-Drug Interactions Associated with Statin-Induced Rhabdomyolysis. *Pharm Med.* 2016 Dec;30(6):327-37.

Wang C, Kane R, Levenson M. et al. Association Between Changes in CMS Reimbursement Policy and Drug Labels for Erythrocyte-Stimulating Agents With Outcomes for Older Patients Undergoing Hemodialysis Covered by Fee-for-Service Medicare. *JAMA Intern Med.* 2016 Dec 1;176(12):1818-1825. doi: 10.1001/jamainternmed.2016.6520.

Major JM, Penberthy L, McGlynn KA. Data systems and record linkage: considerations for pharmacoepidemiologic studies examining cancer risk. *Annals of Epidemiology* 2016 Nov; 26(11):746-748. Epub 2016 Aug 31.

Pinheiro S, Rivera DR, **Graham DJ**, Freedman A, **Major JM**, Penberthy L, Levenson M, Bradley MC, Wong HL, **Ouellet-Hellstrom R**. Challenges in evaluating cancer as a clinical outcome in post-approval studies of drug safety. *Annals of Epidemiology* 2016 2016 Nov; 26(11):735-740. Epub 2016 Aug 31.

Bersoff-Matcha SJ, **Cao K**, **Jason M**, **Ajao A**, **Jones SC**, **Meyer T**, **Brinker A**. Hepatitis B Reactivation Associated with Direct Acting Antiviral Therapy for Hepatitis C: A Review of Spontaneous Post-Marketing Cases. American Association for the Study of Liver Diseases (AASLD) Liver Meeting. November 13, 2016. Boston MA. Poster and abstract #LB-17.

Xu J, Gill R, Cruz M, **Staffa J**, Lurie P. Effect of US Food and Drug Administration-Approved Pediatric Labeling on Dispensing of Extended Release Oxycodone in the Outpatient Retail Setting. *JAMA Pediatr*. 2016 Nov 1;170(11):1103-1104.

Chehab M, **Mohamoud M**, **Gada N**, **Jones SC**, **Chai C**, **Moeny D**. Unapproved Domperidone Use and Cardiac Adverse Events: Data from The FDA Adverse Event Reporting System And US Drug Utilization. October 30-November 2, 2016. Joint Federal Pharmacy Seminar. Washington DC. Poster #27.

Budnitz, DS, Lovegrove MC, Sapiano MRP, **Mathew J**, Kegler SR, Geller AI, **Hampp C**. Pediatric Emergency Department Visits for Buprenorphine/Naloxone Ingestion — United States, 2008–2015. *Morbidity and Mortality Weekly Report, MMWR*. 2016 Oct 65(4): 1148-1149.

Cheng C, **La Grenade L**, **Diak IL**, **Brinker A**, **Levin RL**. Chemical Leukoderma Associated with Methylphenidate Transdermal System: Data From the US Food and Drug Administration Adverse Event Reporting System. *J Pediatr*. 2016 Oct 10. pii: S0022-3476(16)30918-0.

Graham DJ, **Reichman ME**, Wernecke M, et al. Stroke, Bleeding, and Mortality Risks in Elderly Medicare Beneficiaries Treated With Dabigatran or Rivaroxaban for Nonvalvular Atrial Fibrillation. *JAMA Intern Med*. Published online October 03, 2016. doi:10.1001/jamainternmed.2016.5954.

Shah M, **Merchant L**, **Chan I**, **Taylor K**. Characteristics That May Help in the Identification of Potentially Confusing Proprietary Drug Names. *Therapeutic Innovation & Regulatory Science*. September 26, 2016. doi:10.1177/2168479016667161.

Nelson JC, Wellman R, Yu O, Cook AJ, Maro JC, **Ouellet-Hellstrom R**, Boudreau D, Floyd JS, Heckbert SR, **Pinheiro S**, **Reichman M**, Shoaibi A. A Synthesis of Current Surveillance Planning Methods for the Sequential Monitoring of Drug and Vaccine Adverse Effects Using Electronic Health Care Data. *EGEMS (Washington, DC)*. 2016 Sep 6; 4(1):1219.

Li J, **Izem R**. Methods for Interim Analyses in Observational Studies of Medical Product Safety. Poster #290 presented at ICPE, August 2016.

Eworuke E, Shaya F, **Graham DJ**, **Major J**, **Levenson M**, **Chen CY**, **Leishear K**, **Pinheiro S**. Strategies addressing inadequate information on health factors in pharmacoepidemiology studies relying on healthcare databases: commentary from a public workshop. *Pharmacoepidemiol Drug Saf*. 2016 Sep;25(9):998-1001. Epub 2016 Jul 7.

Gruber S, Chakravarty A, Heckbert SR, Levenson M, Martin D, Nelson JC, Psaty BM, **Pinheiro S**, Reich CG, Toh S, Walker AM. Design and analysis choices for safety surveillance evaluations need to be tuned to the specifics of the hypothesized drug-outcome association. *Pharmacoepidemiol Drug Saf.* 2016 Sep;25(9):973-81.

Mott K, Graham DJ, Toh S, Gagne JJ, Levenson M, Ma Y, **Reichman ME**. Uptake of new drugs in the early post-approval period in the Mini-Sentinel distributed database. *Pharmacoepidemiol Drug Saf.* 2016 Sep;25(9):1023-32.

Hwang CS, Kang EM, **Kornegay CJ, Staffa JA, Jones CM, McAninch JK**. Trends in the Concomitant Prescribing of Opioids and Benzodiazepines, 2002-2014. *Am J Prev Med.* 2016 Aug;51(2):151-60.

Wang W, Kreimeyer K, Woo EJ, **Ball R**, Foster M, Pandey A, Scott J, Botsis T. A new algorithmic approach for the extraction of temporal associations from clinical narratives with an application to medical product safety surveillance reports. *J Biomed Inform.* 2016 Aug;62:78-89.

McCulley L, Gelperin K, Bird S, Harris S, Wang C, Waldron P. Reports to FDA of fatal anaphylaxis associated with intravenous iron products. *Am J Hematol.* 2016 Aug 10.

Major JM, Kang EM, Pinheiro S, Zhou EH, Ding Y, Seymour S. Patterns of tiotropium dispensing in the United States and impact of FDA drug safety communications. *Pharmacoepidemiol Drug Saf.* 2016 Aug; 25(Suppl. 3):294 [ICPE Annual Meeting Poster and Abstract #502].

Cunningham FE, Hur K, Dong D, Miller DR, Zhang R, Wei X, McCarren M, **Mosholder AD, Graham DJ**, Aspinall SL, Good CB. A comparison of neuropsychiatric adverse events during early treatment with varenicline or a nicotine patch. *Addiction.* 2016 Jul;111(7):1283-92.

Sekine S, Pinnow EE, Wu E, Kurtzig R, Hall M, Dal Pan GJ. Assessment of the impact of scheduled postmarketing safety summary analyses on regulatory actions. *Clin Pharmacol Ther.* 2016 Jul;100(1):102-8.

Toh S, **Hampp C, Reichman ME, Graham DJ**, Balakrishnan S, Pucino F, Hamilton J, Lendle S, Iyer A, Rucker M, Pimentel M, Nathwani N, Griffin MR, Brown NJ, Fireman BH. Risk for Hospitalized Heart Failure Among New Users of Saxagliptin, Sitagliptin, and Other Antihyperglycemic Drugs: A Retrospective Cohort Study. *Ann Intern Med.* 2016 Jun 7;164(11):705-14.

Epperly H, Vaughn FL, **suc**, Rubinson L. Nonsteroidal Anti-Inflammatory Drug and Aspirin Use, and Mortality among Critically Ill Pandemic H1N1 Influenza Patients: an Exploratory Analysis. *Jpn J Infect Dis.* 2016 May 20;69(3):248-51. doi: 10.7883/yoken.JJID.2014.577. Epub 2015 Aug 7.

Major JM, Zhou EH, Wong HL, Trinidad JP, Pham TM, Mehta H, Ding Y, Staffa JA, Iyasu S, Wang C, Willy ME. Trends in rates of acetaminophen-related adverse events in the United States. *Pharmacoepidemiol Drug Saf.* 2016 May;25(5):590-8.

Wang C, Wong S, Graham DJ. Risk of Anaphylaxis With Intravenous Iron Products. *JAMA.* 2016 May 24-31;315(20):2232-3.

Major JM, Dong D, Cunningham F, By K, Hur K, Shih DC, Podskalny G, **Pinheiro S, Bird ST**, Keeton S, Jiang R, **Graham DJ**. Entacapone and prostate cancer in patients with Parkinson's disease: a large Veterans Health Administration study. April 1-5, 2016. American Association for Cancer Research. Washington DC. Poster #27; Abstract #2303.

Rand M, Arora S, Salaam T, Brinker, A, Proestel S. Pharmacovigilance at FDA: Docetaxel and Alcohol Intoxication. March 16-19,2016. 12th Hematology/Oncology Pharmacy Association (HOPA) Annual Conference, Atlanta, GA.

Duggirala HJ, Tanning JM, Smith E, Bright RA, Baker JD, **Ball R, Bell C**, Bright-Ponte SJ, Botsis T, Bouri K, Boyer M, Burkhart K, Condrey GS, Chen JJ, Chirtel S, Filice RW, Francis H, Jiang H, Levine J, Martin D, Oladipo T, O'Neill R, Palmer LA, Paredes A, Rochester G, Sholtes D, Szarfman A, Wong HL, Xu Z, Kass-Hout T. Use of data mining at the Food and Drug Administration. *J Am Med Inform Assoc.* 2016 Mar;23(2):428-34.

Hampp C, Greene P, Pinheiro SP. Use of Prescription Drug Samples in the USA: A Descriptive Study with Considerations for Pharmacoepidemiology. *Drug Safety* 2016 Mar; 39(3):261-70.

Senior JR. Can rechallenge be done safely after mild or moderate drug-induced liver injury? *Hepatology.* 2016 Mar; 63(3):691-3.

Avigan MI, Mozersky RP, Seeff LB. Scientific and Regulatory Perspectives in Herbal and Dietary Supplement Associated Hepatotoxicity in the United States. *nt J Mol Sci.* 2016 Mar 3;17(3):331.

Hansen C, Andrade SE, Freiman H, Dublin S, Haffenreffer K, Cooper WO, Cheetham TC, Toh S, Li DK, Raebel MA, Kuntz JL, Perrin N, Rosales AG, Carter S, Pawloski PA, **Maloney EM, Graham DJ**, Sahin L, Scott PE, Yap J, Davis R. Trimethoprim-sulfonamide use during the first trimester of pregnancy and the risk of congenital anomalies. *Pharmacoepidemiol Drug Saf.* 2016 Feb;25(2):170-8.

Ball R, Robb M, Anderson SA, Dal Pan G. The FDA's Sentinel initiative-A comprehensive approach to medical product surveillance. *Clin Pharmacol Ther.* 2016 Mar;99(3):265-8. doi: 10.1002/cpt.320. Epub 2016 Jan 12.

Nayernama A, Waldron P, Salaam T, Proestel S. Postmarketing safety review of everolimus and cardiac failure or left ventricular dysfunction. *J Clin Oncol* 34, 2016 (suppl; abstr e18226) ASCO Annual Meeting.

Daley MF, Goddard K, McClung M, **Reichman M**, et al. Using a Handheld Device for Patient Data Collection: A Pilot for Medical Countermeasures Surveillance. *Public health reports (Washington, DC : 1974)* 2016;131:30-4.

Gagne JJ, Han X, Hennessy S, **Meyer T**, et al. Successful Comparison of US Food and Drug Administration Sentinel Analysis Tools to Traditional Approaches in Quantifying a Known Drug-Adverse Event Association. *Clinical pharmacology and therapeutics* 2016.

Butler MG, **Zhou EH**, Zhang F, et al. Changing patterns of asthma medication use related to US Food and Drug Administration long-acting beta2-agonist regulation from 2005-2011. *The Journal of allergy and clinical immunology* 2016;137:710-7.

Baer B, **Nguyen M**, Woo EJ, Winiecki S, Scott J, Martin D, Botsis T, **Ball R.** Can natural language processing improve the efficiency of vaccine adverse event report review? *Methods of Information in Medicine.* 2016, 55(2):144-50.

Andrade SE, Toh S, **Houstoun M**, et al. Surveillance of Medication Use During Pregnancy in the Mini-Sentinel Program. *Maternal and child health journal* 2016;20:895-903.

Andrade SE, **Reichman ME, Mott K**, et al. Use of selective serotonin reuptake inhibitors (SSRIs) in women delivering liveborn infants and other women of child-bearing age within the U.S. Food and Drug Administration's Mini-Sentinel program. *Archives of women's mental health*, 2016.

2015

Racoosin JA, Seymour SM, **Cascio L, Gill R**. Serious neurologic events after epidural glucocorticoid injection - the FDA's risk assessment. *N Engl J Med* 2015 Dec 10;373:2299-2301.

Wang C, Graham DJ, Kane RC, Xie D, et al. Comparative risk of anaphylactic reactions associated with intravenous iron products. *JAMA*. 2015; 314(19):2062-8.

Jones CM, McAninch J. Nonmedical-use related emergency department visits and drug overdose deaths involving the combination of opioid analgesics and benzodiazepines in the United States, 2004-2011. *Am J Prev Med*. 2015;49(4):493-501.

Iarikov D, **Wassel R**, Farley J, Nambiar S. Adverse Events Associated with Fosfomycin Use: Review of the Literature and Analyses of the FDA Adverse Event Reporting System Database. *Infect Dis Ther*. 2015 Dec;4(4):433-58.

Jones SC, Ryan DR, Pratt VSW, **Niak A, Brinker AD**. Injection site nodules associated with the use of exenatide extended-release for injectable suspension reported to the FDA Adverse Event Reporting System (FAERS). *Diabetes Spectrum*. 2015 Nov; 28(4): 283-288.

Major JM, Zhou EH, Wong HL, Trinidad JP, Pham TM, Mehta H, Ding Y, Staffa JA, Iyasu S, Wang C, Willy ME. Trends in rates of acetaminophen-related adverse events in the United States *Pharmacoepidemiol Drug Saf*. 2015 Nov 3. doi: 10.1002/pds.3906.

McMahon AW, Wharton GT, Bonnel R, DeCelle M, **Swank K**, Testoni D, Cope JU, Smith PB, **Wu E**, Murphy MD. Pediatric post-marketing safety systems in North America: assessment of the current status. *Pharmacoepidemiology and Drug Safety* 2015 Aug;24(8):785-92. Epub 2015 Jun 22.

Kesselheim AS, Campbell EG, Schneeweiss S, Rausch P, Lappin BM, **Zhou EH**, Seeger JD, Brownstein JS, Woloshin S, Schwartz LM, Toomey T, **Dal Pan GJ**, Avorn J. Methodological Approaches to Evaluating the Impact of FDA Drug Safety Communications. *Drug Saf*. 2015 Jun;38(6):565-75.

Bohn J, **Kortepeter C, Muñoz MA, Simms K, Dal Pan G**. Patterns in spontaneous adverse event reporting among branded and generic antiepileptic drugs. *Clin Pharmacol Ther*. 2015 May;97(5):508-17.

Knox C, **Hampp C, Willy M**, Winterstein AG, **Dal Pan G**. Patient Understanding of Drug Risks: Analysis of Medication Guide Assessments. *Pharmacoepidemiol Drug Saf*. 2015 Mar; 24: 518–525.

Graham DJ, Reichman ME, Wernecke M, Zhang R, Southworth MR, Levenson M, Sheu TC, **Mott K, Goulding MR, Houstoun M**, MaCurdy TE, Worrall C, Kelman JA. Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. 2015 Jan 13;131(2):157-64. doi: 10.1161/CIRCULATIONAHA.114.012061. Epub 2014 Oct 30.

Li J, Goulding M, Seymour S, Starke P. EXCELS study results do not rule out potential cancer risk with omalizumab. *J Allergy Clin Immunol.* 2015 Jan;135(1):289. doi: 10.1016/j.jaci.2014.09.017. Epub 2014 Oct 29.

Davis RL, Gallagher MA, Asgari MM, Eide MJ, Margolis DJ, Macy E, Burmester JK, Selvam N, Boscarino JA, Cromwell LF, Feigelson HS, Kuntz JL, Pawloski PA, Penfold RB, Raebel MA, Sridhar G, Wu A, **La Grenade LA**, Pacanowski MA, **Pinheiro SP.** Identification of Stevens-Johnson syndrome and toxic epidermal necrolysis in electronic health record databases. *Pharmacoepidemiol Drug Saf.* 2015 Jul;24(7):684-92. PMID: 25914229

Kang EM, Pinheiro SP, Hammad TA, Abou-Ali A. Evaluating the validity of clinical codes to identify cataract and glaucoma in the UK Clinical Practice Research Datalink. *Pharmacoepidemiol Drug Saf.* 2015 Jan;24(1):38-44. PMID: 25425327

2014

Secora AM, Dormitzer CM, Staffa JA, Dal Pan. GJ. Measures to quantify the abuse of prescription opioids: a review of data sources and metrics. *Pharmacoepidemiol Drug Saf.* 2014 Dec;23(12):1227-37. doi: 10.1002/pds.3711. Epub 2014 Sep 25. Review. PMID:25257660

Zhou EH, Kang EM, Seymour S, and Iyasu S. Long-Acting Beta-Adrenergic Agonist Use in Pediatric and Adolescent Asthma Patients, 2003-2011 *Journal of Asthma.* Dec 2014, Vol. 51, No. 10: 1061–1067. 2014 Jul 17:1-7. [Epub ahead of print]

Bell C, Chakravarty A, Gruber S, Heckbert SR, Levenson M, Martin D, Nelson JC, **Pinheiro S,** Psaty BM, Reich CG, Schneeweiss S, Shoaibi A, Toh S, Walker AM. Characteristics of study design and elements that may contribute to the success of electronic safety monitoring systems. *Pharmacoepidemiol Drug Saf* 2014 Nov;23(11):1223-5

Graham DJ, By K, McKean S, **Mosholder A, Kornegay C,** Racoosin JA, Young J, Levenson M, MaCurdy TE, Worrall C, Kelman JA. Cardiovascular and mortality risks in older Medicare patients treated with varenicline or bupropion for smoking cessation: an observational cohort study. *Pharmacoepidemiol Drug Saf* 2014 Nov;23(11):1205-12

Raebel MA, Penfold R, McMahon AW, **Reichman M,** Shetterly S, Goodrich G, Andrade S, Correll CU, Gerhard T. Adherence to guidelines for glucose assessment in starting second-generation antipsychotics. *Pediatrics* 2014 Nov;134(5):e1308-14

Avigan MI, Bjornsson ES, Pasanen M, Cooper C, Andrade RJ, Watkins PB, Lewis JH, Merz M. Liver safety assessment: required data elements and best practices for data collection and standardization in clinical trials. *Drug Saf* 2014 Nov;37 Suppl 1:19-31

Senior JR. Evolution of the Food and Drug Administration approach to liver safety assessment for new drugs: current status and challenges. *Drug Saf* 2014 Nov;37 Suppl 1:9-17

Beckmann J, Hagemann U, Bahri P, Bate A, Boyd IW, **Dal Pan GJ,** Edwards BD, Edwards IR, Hartigan-Go K, Lindquist M, McEwen J, Moride Y, Olsson S, Pal SN, Soulaymani-Bencheikh R, Tuccori M, Vaca CP, Wong IC. Teaching pharmacovigilance: the WHO-ISoP core elements of a comprehensive modular curriculum. *Drug Saf.* 2014 Oct;37(10):743-59. doi: 10.1007/s40264-014-0216-1.

Graham DJ, Reichman ME, Wernecke M, Zhang R, Southworth MR, Levenson M, Sheu TC, **Mott K, Goulding MR, Houstoun M,** MaCurdy TE, Worrall C, Kelman JA. Cardiovascular, Bleeding, and Mortality Risks in Elderly Medicare Patients Treated with Dabigatran or Warfarin for Non-Valvular Atrial Fibrillation. *Circulation* 2014 Oct 30 [Epub ahead of print].

Mosholder AD, Taylor LG, Crentsil V. Reservations about study on antidepressant use by young people and suicidal behaviour after FDA warnings. *BMJ* 2014 Oct 29;349:g6503

Li J, Goulding M, Seymour S, Starke P. EXCELS study results do not rule out potential cancer risk with omalizumab. *J Allergy Clin Immunol* 2014 Oct 29 [Epub ahead of print]

Ghods MP, Schmid IT, **Pamer CA,** Lappin BM, Slavin DC. Developing and Initiating Validation of a Model Opioid Patient-Prescriber Agreement as a Tool for Patient-Centered Pain Treatment. *Patient* 2014 Oct 26 [Epub ahead of print]

Kurz X, Martin D, Hoekman J, Bouvy JC, Roddam A, Ebbers H, Leufkens HGM, Chan KA, **Dal Pan G,** Reynolds R, De Bruin ML. Challenges in Implementing Findings of Regulatory Science to Evaluate and Improve the Drug Regulatory System. *Pharmacoepidemiol Drug Saf* 2014 Oct;23(Suppl. S1):204-5

Andrade S, Toh S, Pitts M, **Houstoun M, Mott K,** Haffenreffer K, **Reichman M.** Evaluation of Medication Use During Pregnancy in the Mini-Sentinel Distributed Database. *Pharmacoepidemiol Drug Saf* 2014 Oct;23(Suppl. S1):314-5

Edlavitch SA, **Dal Pan GJ,** Raine JM, Leufkens HG, Park BJ, Avorn J. Improving the Science of Regulatory Decision-Making - Advances in 2013/2014. *Pharmacoepidemiol Drug Saf* 2014 Oct;23(Suppl. S1):340

Chen C, Eworuke E, Schelfhout J, Hartzema A. Hospital Volume and Outcomes for Total Hip Arthroplasty. *Pharmacoepidemiol Drug Saf* 2014 Oct;23(Suppl. S1):488-9

Hallas J, Rothman KJ, Kubota K, Blackburn S, Navarro AA, **Dal Pan G.** A Guide to Guidelines. A Symposium Sponsored by the Public Policy Committee. *Pharmacoepidemiol Drug Saf* 2014 Oct;23(Suppl. S1):40

Dal Pan G, Ehrenstein V, John S, Thyagarajan V, Wright NC, Xu HR, Xue F. Confirmation of Medical Events (ME) Identified from Existing Electronic Databases in Pharmacoepidemiology (PE) Studies *Pharmacoepidemiol Drug Saf* 2014 Oct;23(Suppl. S1):337-8

Smith M, Bahri P, **Dal Pan G,** Banerjee S, Mol P, Dey D. The Patient's Voice in the Heart of BRACE (Benefit-Risk Assessment, Communication and Evaluation) *Pharmacoepidemiol Drug Saf* 2014 Oct;23(Suppl. S1):364-5.

Viswanathan P, Iarikov D, **Wassel R,** Davidson A, Nambiar S. Hypoglycemia in patients treated with linezolid. *Clin Infect Dis* 2014 Oct 15;59(8):e93-5

Lovegrove MC, **Mathew J, Hampp C, Governale L, Wysowski DK,** Budnitz DS. Emergency hospitalizations for unsupervised prescription medication ingestions by young children. *Pediatrics* 2014 Oct;134(4):e1009-16.

Hartman NR, Mao JJ, Zhou H, Boyne MT 2nd, Wasserman AM, **Taylor K**, Racoosin JA, Patel V, Colatsky T. More methemoglobin is produced by benzocaine treatment than lidocaine treatment in human in vitro systems. *Regul Toxicol Pharmacol* 2014 Oct;70(1):182-8.

Beckmann J, Hagemann U, Bahri P, Bate A, Boyd IW, **Dal Pan GJ**, Edwards BD, Edwards IR, Hartigan-Go K, Lindquist M, McEwen J, Moride Y, Olsson S, Pal SN, Soulaymani-Bencheikh R, Tuccori M, Vaca CP, Wong IC. Teaching pharmacovigilance: the WHO-ISoP core elements of a comprehensive modular curriculum. *Drug Saf* 2014 Oct;37(10):743-59.

Watkins PB, Merz M, **Avigan MI**, Kaplowitz N, Regev A, **Senior JR**. The Clinical Liver Safety Assessment Best Practices Workshop: Rationale, Goals, Accomplishments, and the Future. *Drug Saf* (2014) 37 (Suppl 1):S1–S7; Published online 2014 Oct 29. DOI 10.1007/s40264-014-0181-8

Hartman NH, Mao JJ, Zhou H, Boyne II MT, Wasserman AM, **Taylor K**, Racoosin JA, Patel V, Colatsky T. More Methemoglobin is Formed by Benzocaine than Lidocaine in Human In Vitro Systems. *Regul Toxicol Pharmacol*. 2014 Oct;70(1):182-8. doi: 10.1016/j.yrtph.2014.07.002. Epub 2014 Jul 8.

Eworuke E, Lensa Zeng QY, Winterstein AG. Clinical and sociodemographic factors associated with attention-deficit/hyperactivity disorder in patients with cystic fibrosis. *Psychosomatics* 2015 Sep-Oct;56(5):495-503. doi: 10.1016/j.psych.2014.09.001. Epub 2014 Sep 6.

Cross AJ, **Major JM**, Rothman N, Sinha R. Urinary 1-methylhistidine and 3-methylhistidine, meat intake, and colorectal adenoma risk. *Eur J Cancer Prev*. 2014 Sep;23(5):385-90. doi: 10.1097/CEJ.0000000000000027.

Houstoun M, **Reichman ME**, **Graham DJ**, Nambiar S, Shamsuddin H, Jones SC, **Cao K**, Wernecke M, Lam C, Worrall CM, MaCurdy TE, Kelman JA. Use of an active surveillance system by the FDA to observe patterns of quinine sulfate use and adverse hematologic outcomes in CMS Medicare data. *Pharmacoepidemiol Drug Saf* 2014 Sep;23(9):911- 7

Margulis AV, **Kang EM**, **Hammad TA**. Patterns of Prescription of Antidepressants and Antipsychotics Across and Within Pregnancies in a Population-Based UK Cohort. *Matern Child Health J* 2014 Sep;18(7):1742-52

Willy ME, **Graham DJ**, Racoosin JA, **Gill R**, Kropp GF, Young J, Yang J, Choi J, MaCurdy TE, Worrall C, Kelman JA. Candidate Metrics for Evaluating the Impact of Prescriber Education on the Safe Use of Extended-Release/Long-Acting (ER/LA) Opioid Analgesics. *Pain Med* 2014 Sep;15(9):1558-68

Amiri-Kordestani L, Blumenthal GM, Xu QC, Zhang L, Tang SW, Ha L, Weinberg WC, Chi B, Candau-Chacon R, Hughes P, Russell AM, Pope Miksinski S, Chen XH, McGuinn WD, Palmby T, Schrieber SJ, Liu Q, Wang J, Song P, Mehrotra N, **Skarupa L**, Clouse K, Al-Hakim A, Sridhara R, Ibrahim A, Justice R, Pazdur R, Cortazar P. FDA Approval: Ado-trastuzumab Emtansine for the Treatment of Patients with HER2-Positive Metastatic Breast Cancer. *Clin Cancer Res* 2014 Sep 1;20(17):4436-41

Maro JC, Brown JS, **Dal Pan GJ**, Kulldorff M. Minimizing signal detection time in postmarket sequential analysis: balancing positive predictive value and sensitivity. *Pharmacoepidemiol Drug Saf* 2014 Aug;23(8):839-48. Epub 2014 Apr 3.

Winterstein AG, Kubilis P, **Bird S**, Cooper-DeHoff RM, Nichols GA, Delaney JA. Misclassification in assessment of diabetogenic risk using electronic health records. *Pharmacoepidemiol Drug Saf* 2014 Aug;23(8):875-81

Franks R, Sandhu S, Avagyan A, Lu Y, Hong H, Garcia B, Worrall C, Kelman J, **Ball R**, MaCurdy T. Robustness Properties of a Sequential Test for Vaccine Safety in the Presence of Misspecification. *Statistical Analysis and Data Mining* 19 AUG 2014 DOI: 10.1002/sam.11234.

Markatou M, **Ball R**. A Pattern Discovery Framework for Adverse Event Evaluation and Inference in Spontaneous Reporting Systems. *Statistical Analysis and Data Mining* 14 AUG 2014 DOI: 10.1002/sam.11233.

Botsis T, Scott J, Woo EJ, **Ball R**. Identifying Similar Cases in Document Networks using Cross-reference Structures. *IEEE J Biomed Health Inform* 2014 Aug 7 [Epub ahead of print]

Wharton GT, Murphy MD, Avant D, Goldsmith JV, **Chai G**, Rodriguez WJ, Eisenstein EL. Impact of Pediatric Exclusivity on Drug Labeling and Demonstrations of Efficacy. *Pediatrics*. 2014 Aug; 134(2):512-518.

Zhou EH, Kang EM, Seymour S, and **Iyasu S**. Long-Acting Beta-Adrenergic Agonist in Pediatric and Adolescent Asthma Patients, 2003–2011. *J Asthma*. 2014 Jun 19:1-26

Hampp C, Borders-Hemphill V, Moeny DG, Wysowski DK. Use of Antidiabetic Drugs in the United States, 2003-2012. *Diabetes Care*. 2014 May; 37(5):1367-74.

James P, Berrigan D, Hart JE, Hipp JA, Hoehner CM, Kerr J, **Major JM**, Oka M, Laden F. Effects of buffer size and shape on associations between the built environment and energy balance. *Health Place*. 2014 May;27:162-70. doi: 10.1016/j.healthplace.2014.02.003. Epub 2014 Mar 7.

Avigan MI. DILI and Drug Development: A Regulatory Perspective. *Semin Liver Dis* 2014 May;34(2):215-26

Major JM, Yu K, Weinstein SJ, Berndt SI, Hyland PL, Yeager M, Chanock S, Albanes D. Genetic variants reflecting higher vitamin e status in men are associated with reduced risk of prostate cancer. *J Nutr* 2014 May;144(5):729-33

Sahin L, **Gelperin K, Hammad H, Nguyen M**, Woo J, **Iyasu S**. US FDA Systematic Review and Preliminary Analysis of Pregnancy Registries Birth Defects Res A Clin Mol Teratol 2014 May;100(5):394

Zhou EH, Gelperin K, Levenson MS, Rose M, Hsueh YH, **Graham DJ**. Risk of acute myocardial infarction, stroke, or death in patients initiating olmesartan or other angiotensin receptor blockers - a cohort study using the Clinical Practice Research Datalink. *Pharmacoepidemiol Drug Saf*. 2014 Apr;23(4):340-7.

Graham DJ, Zhou EH, McKean S, Levenson M, Calia K, **Gelperin K**, Ding X, MaCurdy TE, Worrall C, Kelman JA. Cardiovascular and mortality risk in elderly Medicare beneficiaries treated with olmesartan versus other angiotensin receptor blockers. *Pharmacoepidemiol Drug Saf*. 2014 Apr;23(4):331-9. Epub 2013 Nov 26.

Ball R. Perspectives on the future of postmarket vaccine safety surveillance and evaluation. *Expert Rev Vaccines* 2014 Apr;13(4):455-62

Scott J, Botsis T, **Ball R**. Simulating adverse event spontaneous reporting systems as preferential attachment networks: Application to the Vaccine Adverse Event Reporting System. 2014 Mar 5;5(1):206-18. doi: 10.4338/ACI-2013-11-RA-0097. eCollection 2014.

Fine AJ, Sorbello A, Kortepeter C. Progressive Multifocal Leukoencephalopathy after Natalizumab Discontinuation: Few and True? – Reply Ann Neurol 2014 Mar;75(3):462-3

Senior JR. New biomarkers for drug-induced liver injury: are they really better? what do they diagnose? Liver Int 2014 Mar;34(3):325-7

Major JM, Sargent JD, Graubard BI, Carlos HA, Hollenbeck AR, Altekruse SF, Freedman ND, McGlynn KA. Local geographic variation in chronic liver disease and hepatocellular carcinoma: contributions of socioeconomic deprivation, alcohol retail outlets, and lifestyle. Ann Epidemiol 2014 Feb;24(2):104-10.

Major JM, Sargent JD, Graubard BI, Carlos HA, Hollenbeck AR, Altekruse SF, Freedman ND, McGlynn KA. Local geographic variation in chronic liver disease and hepatocellular carcinoma: contributions of socioeconomic deprivation, alcohol retail outlets, and lifestyle. Ann Epidemiol 2014 Feb;24(2):104-10

Chen M-C, Iyasu S, Sorbello A, Scarazzini L. Spontaneous Reporting and Pharmacovigilance Practice: USA In: Andrews E, Moore N, eds. Mann's Pharmacovigilance. 3rd ed. Chichester, West Sussex, UK: Wiley Blackwell; 2014:229-240.

Willett, C., Caverly Rae, J., Goyak, K.O., Minsavage, G., Westmoreland, C., Andersen, M., **Avigan, M.**, Duché, D., Harris, G., Hartung, T., Jaeschke, H., Kleensang, H., Landesmann, B., Martos, S., Matevia, M., Toole, C., Rowan, G., Schultz, T., Seed, J., Senior, J., Shah, I., Subramanian, K., Vinken, M., and Watkins, P. Building shared experience to advance practical application of pathway-based toxicology: Liver Toxicity Mode-of-Action. ALTEX Epub. Feb 17, 2014 [online: <http://dx.doi.org/10.14573/altex.1401281>]

Wysowski DK. Reply to: Effect of pharmacological treatment of osteoporosis in the prevention of pathological vertebral fractures. Bone 2014 Feb;59:150

Iyasu S, Staffa J, Graham D, Shoaibi A, Levenson M, Chakravarty A, **Hammad TA**. Drug risk assessment and data reuse Pharmacoepidemiol Drug Saf. 2014 Jan;23(1):107-8. doi: 10.1002/pds.3518.

Stone MB, **Hammad TA**. Fluoxetine and suicidal ideation in minor depression. J Psychiatr Res 2014 Jan;48(1):131-2.

Fine AJ, **Sorbello A, Kortepeter C, Scarazzini L**. Progressive multifocal leukoencephalopathy after natalizumab discontinuation. Ann Neurol 2014 Jan;75(1):108-15

Dal Pan, GJ. Ongoing challenges in pharmacovigilance. Drug Saf 2014 Jan;37(1):1-8

Avalos LA, Chen H, Yang C, Andrade SE, Cooper WO, Cheetham CT, Davis RL, Dublin S, **Hammad TA, Kaplan S**, Pawloski PA, Raebel MA, Scott PE, Smith DH, Toh S, Li DK. The Prevalence and Trends of Antiviral Medication Use During Pregnancy in the US: A Population-Based Study of 664,297 Deliveries in 2001-2007. Matern Child Health J 2014 Jan;18(1):64-72

Bird ST, Crentsil V, Temple R, **Pinheiro S**, Demczar D, Stone M. Cardiac Safety Concerns Remain for Citalopram at Dosages Above 40 mg/Day. *Am J Psychiatry* 2014 Jan;171(1):17-9.

Botsis T, Scott J, Goud R, Toman P, Sutherland A, **Ball R**. Novel Algorithms for Improved Pattern Recognition Using the US FDA Adverse Event Network Analyzer. *Stud Health Technol Inform* 2014;205:1178-82.

Iarikov D, **Wassel R**, Farley J, Nambiar S. Adverse Events Associated with Fosfomycin--Analyses of the U.S. FDA Adverse Event Reporting System (FAERS) and Review of the Literature. Meeting Abstract.

Godfrey C, Payton M, Tasker **S**, **Proestel S**, Schouten J. Ensuring Participant Safety and Trial Integrity With Clinical Trials Oversight. *J Acquir Immune Defic Syndr* 2014 Jan;65:S40-S43

2013

Hampp C, **Kang E**, **Borders-Hemphill V**. Use of Prescription Antiobesity Drugs in the United States. *Pharmacotherapy*, 2013 Dec; 33(12):1299-1307.

Pinheiro SP, **Kang EM**, Kim CY, **Governale LA**, **Zhou EH**, **Hammad TA**. Concomitant use of isotretinoin and contraceptives before and after iPledge in the United States. *Pharmacoepidemiol Drug Saf*. 2013 Dec;22(12):1251-7. PMID: 23913625

Hammad TA, **Neyarapally GA**, **Pinheiro SP**, **Iyasu S**, Rochester G, **Dal Pan G**. Reporting of meta-analyses of randomized controlled trials with a focus on drug safety: an empirical assessment. *Pharmacoepidemiol Drug Saf*. 2013 Dec;22(12): PMID: 23913625

Brinker AD, **Lyndly J**, **Tonning J**, **Moeny D**, Levine JG, **Avigan MI**. Profiling Cumulative Proportional Reporting Ratios of Drug-Induced Liver Injury in the FDA Adverse Event Reporting System (FAERS) Database. *Drug Safety* 2013 Dec;36(12):1169-78.

Graham DJ, **Zhou EH**, McKean S, Levenson M, Calia K, **Gelperin K**, Ding X, Macurdy TE, Worrall C, Kelman JA. Cardiovascular and mortality risks in elderly Medicare beneficiaries treated with olmesartan vs. other angiotensin receptor blockers. *Pharmacoepidemiol Drug Saf*. 2013 Nov 26. doi: 10.1002/pds.3548.

Manthripragada AD, **Pinheiro SP**, MaCurdy TE, Saneinejad S, Worrall CM, Kelman JA, Graham DJ. Off-label topical calcineurin inhibitor use in children. *Pediatrics*. 2013 Nov;132(5):e1327-32. PMID: 24127469.

Solomon DH, Rassen JA, Kuriya B, Chen L, Harrold LR, **Graham DJ**, Lewis JD, Lii J, Liu L, Griffin MR, Curtis JR. Heart Failure Risk Among Patients with Rheumatoid Arthritis Starting a TNF Antagonist. *Ann Rheum Dis*. 2013 Nov;72(11):1813-8. doi: 10.1136/annrheumdis-2012-202136. Epub 2012 Nov 15.

Margulis AV, Abou-Ali A, Strazzeri MM, **Ding Y**, **Kuyateh F**, Frimpong EY, Levenson MS, and **Hammad TA**. Use of selective serotonin reuptake inhibitors in pregnancy and cardiac malformations: a propensity-score matched cohort in CPRD. *Pharmacoepidemiol Drug Safety* 2013 Sep;22(9):942-51. doi: 10.1002/pds.3462. Epub 2013 Jun 3.

Solomon DH, Curtis JR, Saag KG, Lii J, Chen L, Harrold LR, Herrinton LJ, **Graham DJ**, Kowal MK, Kuriya B, Liu L, Griffin MR, Lewis JD, Rassen JA. The Relationship of Cardiovascular Risk in

Rheumatoid Arthritis Comparing TNF α Blockade with Non-Biologic DMARDs. *Am J Med.* 2013 Aug; 126(8): 730.e9–730.e17.

Zhou EH, Kaplan S, Mosholder M, Money D, Ding Y, Iyasu S, Hammad TA. Antidepressant medication dispensing among montelukast initiators. *J Asthma.* 2013 Nov;50(9):990-5. doi: 10.3109/02770903.2013.823445. Epub 2013 Aug 20.

Fine AJ, Sorbello A, Kortepeter C, Scarazzini L. Central nervous system herpes simplex and varicella zoster virus infections in natalizumab-treated patients. *Clin Infect Dis.* 2013 Sep;57(6):849-52.

Pinheiro SP, Kang EM, Kim CY, Governale LA, Zhou EH, Hammad TA. Concomitant use of isotretinoin and contraceptives before and after iPledge in the United States. *Pharmacoepidemiol Drug Saf.* 2013 Aug 3. doi: 10.1002/pds.3481. [Epub ahead of print]. PMID: 23913625

Lo Re V 3rd, Haynes K, Goldberg D, Forde KA, Carbonari DM, Leidl KB, Hennessy S, Reddy KR, Pawloski PA, Daniel GW, Cheatham TC, Iyer A, Coughlin KO, Toh S, Boudreau DM, Selvam N, Cooper WO, Selvan MS, VanWormer JJ, **Avigan MI, Houstoun M, Zornberg GL**, Racoosin JA, Shoaibi A. Validity of diagnostic codes to identify cases of severe acute liver injury in the US Food and Drug Administration's Mini-Sentinel Distributed Database. *Pharmacoepidemiol Drug Saf.* 2013 Aug;22(8):861-72.

Hammad TA, Neyarapally GA, Iyasu S, Staffa JA, Dal Pan G. The Future of Population-Based Postmarket Drug Risk Assessment: A Regulator's Perspective. *Clinical Pharmacology & Therapeutics*, advance online publication 10 July 2013. doi:10.1038/clpt.2013.118.

Kawai VK, Grijalva CG, Arbogast PG, Curtis JR, Solomon DH, Delzell E, Chen L, **Ouellet-Hellstrom R**, Herrinton L, Liu L, Mitchell EF, Stein CM, and Griffin M. Initiation of Tumor Necrosis Factor Antagonists and Risk of Fractures in Patients With Selected Rheumatic and Autoimmune Diseases. *Arthritis Care Res (Hoboken).* 2013 Jul;65(7):1085-94. doi: 10.1002/acr.21937.

Dal Pan, G. Commentary on “The Effectiveness of Varenicline Medication Guide for Conveying Safety Information to Patients: a REMS Assessment Survey” by Enger et al. *Pharmacoepidemiol Drug Saf.* 2013 Jul;22(7):716-8. doi: 10.1002/pds.3450. Epub 2013 May 9.

Cooper-DeHoff, RM, **Bird, ST**, Nichols, GA, Delaney, JA, Winterstein, AG. Antihypertensive Drug Class Interactions and Risk for Incident Diabetes: A Nested Case-Control Study. *J Am Heart Assoc.* 2013 Jun 10;2(3):e000125. doi: 10.1161/JAHA.113.000125.

Senior JR. Why the threshold criteria should not be modified for detection of possibly serious drug-induced hepatotoxicity in special groups of trial subjects. *Pharmacoepidemiol Drug Saf.* 2013 Jun;22(6):579-82.

Gatti J, Brinker A, Avigan M. Spontaneous Reports of Seizure in Association with Lupron, Synarel, and Zoladex. Letter to the Editor. *Obstet Gynecol.* 2013 May;121(5):1107. doi: 10.1097/AOG.0b013e31828c9cb3.

Li Q, Andrade SE, Cooper WO, Davis RL, Dublin S, **Hammad TA**, Pawloski PA, **Pinheiro SP**, Raebel MA, Scott PE, Smith DH, Dashevsky I, Haffenreffer K, Jonhson KE, Toh S. Validation of an algorithm to estimate gestational age in electronic health plan databases. *Pharmacoepidemiology in Drug Safety* 2013 May;22(5):524-32. doi: 10.1002/pds.3407. Epub 2013 Jan 21.

Taylor, KA, Holquist, CA. Letter to the Editor. In Defense of X and Z. More on Confusion of Drug Names. *N Engl J Med* 2013 May 16; 368:1946-1947. DOI: 10.1056/NEJMc1302801

Mosholder AD, Mathew J, Alexander JJ, Smith H, Nambiar S. Cardiovascular risks with azithromycin and other antibacterial drugs. *N Engl J Med.* 2013 May 2;368:1665-8.

Beukelman T, Xie F, Baddley JW, Chen L, Delzell E, Grijalva CG, Mannion ML, Patkar NM, Saag KG, Winthrop KL, Curtis JR; **SABER Collaboration.** Brief report: incidence of selected opportunistic infections among children with juvenile idiopathic arthritis. *Arthritis Rheum.* 2013 May;65(5):1384-9. doi: 10.1002/art.37866.

Bird, ST, Hartzema, AG, Etminan, M, Brophy, JM, Delaney, JAC. Polycystic ovary syndrome and combined oral contraceptive use; A comparison of clinical practice in the United States to treatment guidelines. *Gynecol Endocrinol* 2013 Apr;29(4):365-9. doi: 10.3109/09513590.2012.743007. Epub 2013 Jan 11.

Graham DJ, Williams JR, Hsueh YH, Calia K, Levenson M, **Pinheiro SP,** Macurdy TE, **Shih D,** Worrall C, Kelman JA. Cardiovascular and mortality risks in Parkinson's disease patients treated with entacapone. *Mov Disord.* 2013 Apr;28(4):490-7.. PMID: 23443994

Toh S, Li Q, Cheetham TC, Cooper WO, Davis RL, Dublin S, **Hammad TA,** Li DK, Pawloski PA, **Pinheiro SP,** Raebel MA, Scott PE, Smith DH, Bobo WV, Lawrence JM, Dashevsky I, Haffenreffer K, Avalos LA, Andrade SE. Prevalence and trends in the use of antipsychotic medications during pregnancy in the U.S., 2001-2007: a population-based study of 585,615 deliveries. *Arch Womens Ment Health.* 2013 Apr;16(2):149-57. PMID: 23389622

Southworth MR, **Reichman ME,** Unger, EF. Dabigatran and Postmarketing Reports of Bleeding. *N Engl J Med* 2013; 368:1272-1274 April 4, 2013 DOI: 10.1056/NEJMp1302834.

Lester J, **Neyarapally GA,** Lipowski E, **Graham CF, Hall M, and Dal Pan G.** Evaluation of FDA safety-related drug label changes in 2010. *Pharmacoepidemiol Drug Saf.* 2013 Mar;22(3):302-5. doi: 10.1002/pds.3395. Epub 2013 Jan 2.

Hammad TA, Neyarapally GA, Pinheiro SP, Iyasu S, Rochester G, Dal Pan G. Reporting of meta-analyses of randomized controlled trials with a focus on drug safety: An empirical assessment. *Clin Trials.* 2013;10(3):389-97. doi: 10.1177/1740774513479467. Epub 2013 Mar 18.

Bird ST, Hartzema AG, Brophy JM, Etminan M, Delaney JAC. Risk for venous thromboembolism in women with polycystic ovary syndrome; a population-based matched cohort analysis. *CMAJ.* 2013 Feb 5;185(2):E115-20. doi: 10.1503/cmaj.120677. Epub 2012 Dec 3

McLWhorn MW, Goulding MR, Gill RK, Michele TM. Analysis of benzonatate overdoses among adults and children from 1969-2010 by the United States Food and Drug Administration. *Pharmacotherapy.* 2013 Jan;33(1):38-43. doi: 10.1002/phar.1153.

Andrade SE, Scott PE, Davis RL, Li DK, Getahun D, Cheetham TC, Raebel MA, Toh S, Dublin S, Pawloski PA, **Hammad TA,** Beaton SJ, Smith DH, Dashevsky I, Haffenreffer K, Cooper WO. Validity of Health Plan and Birth Certificate Data for Pregnancy Research. *Pharmacoepi and Drug Safety.* 2013 Jan;22(1):7-15. doi: 10.1002/pds.3319. Epub 2012 Jul 3.

Toh S, **Reichman ME**, **Houstoun M**, Ross Southworth M, Ding X, Hernandez AF, Levenson M, Li L, **McCloskey C**, Shoaibi A, **Wu E**, **Zornberg G**, Hennessy S. Comparative risk of angioedema associated with the use of drugs that target the renin-angiotensin-aldosterone system. *Arch Intern Med*. 2013 Jan 14;173(1):14.

Lawrence JM, Andrade SE, Avalos LA, Beaton SJ, Chiu VY, Davis RL, Dublin S, Pawloski PA, Raebel MA, Smith DH, Toh S, Wang JQ, Kaplan S, Amini T, **Hampp C**, **Hammad TA**, Scott PE, Cheetham TC; for the Medication Exposure in Pregnancy Risk Evaluation Program (MEPREP) Study Group. Prevalence, Trends, and Patterns of Use of Antidiabetic Medications among Pregnant Women in the United States, 2001-2007. *Obstet Gynecol*. 2013 Jan;121(1):106-114.

Sidney S, Cheetham TC, Connell FA, **Ouellet-Hellstrom R**, **Graham DJ**, Davis D, Sorel M, Quesenberry, Jr. CP, Cooper WO. Recent combined hormonal contraceptives (CHCs) and the risk of thromboembolism and other cardiovascular events in new users. *Contraception*. 2013 Jan;87(1):93-100. doi: 10.1016/j.contraception.2012.09.015. Epub 2012 Oct 19.

Neugebauer R, Chandra M, Paredes A, **Graham DJ**, **McCloskey C**, and Go AS. A Marginal Structural Modeling Approach with Super Learning for a Study on Oral Bisphosphonate Therapy and Atrial Fibrillation. *Journal of Causal Inference*. 2013 Jan; 1(1): 21–50.

Meyer TE, Taylor LG, Xie S, **Graham DJ**, **Mosholder AD**, Williams JR, **Moeny D**, **Ouellet-Hellstrom RP**, Coster TS. Neuropsychiatric events in varenicline and nicotine replacement patch users in the Military Health System. *Addiction*. 2013 Jan;108(1):203-10. doi: 10.1111/j.1360-0443.2012.04024.x. Epub 2012 Oct 18.

Haynes K, Beukelman T, Curtis JR, Newcomb C, Herrinton LJ, **Graham DJ**, Solomon DH, Griffin MR, Chen L, Liu L, Saag KG, Lewis JD; **SABER Collaboration**. Tumor necrosis factor α inhibitor therapy and cancer risk in chronic immune-mediated diseases. *Arthritis Rheum*. 2013 Jan;65(1):48-58. doi: 10.1002/art.37740.

2012

Kaplan S, **Zhou EH**, **Iyasu S**. Characterization of Long-Acting Beta(2)-Adrenergic Agonists Utilization in Asthma Patients. *J Asthma*. 2012 Oct 30. [Epub ahead of print] *J Asthma*. 2012 Dec;49(10):1079-85.

Ishiguro C, **Hall M**, **Neyarapally GA**, **Dal Pan G**. Post-market drug safety evidence sources: an analysis of FDA drug safety communications. *Pharmacoepidemiol Drug Saf*. 2012 Oct;21(10):1134-6. doi: 10.1002/pds.3317.

Du D, **Zhou EH**, Goldsmith J, Nardinelli C, Hammad T. Use during a Period of FDA Actions. *Medical Care*. 2012 Nov; 50(11):987-92.

Vincent A, Brimmer DJ, Whipple MO, Jones JZ, Boneva R, Lahr BD, **Maloney E**, St. Sauver J, Reeves WC. Prevalence and Incidence of Chronic Fatigue Syndrome in Olmsted County, Minnesota, as Estimated Using the Rochester Epidemiology Project. *Mayo Clin Proc*. 2012 Dec;87(12):1145-52. doi: 10.1016/j.mayocp.2012.08.015. Epub 2012 Nov 8.

Bobo WV, Davis RL, Toh S, Li D, Andrade S., Cheetham TC, Pawloski P, Dublin S, **Pinheiro SP**, **Hammad T**, Scott P, Esptein RA, Arbogast PG, Morrow JA, Dudley JA, Lawrence JM, Avalos LA, Cooper WO. Trends in the use of antiepileptic drugs among pregnant women in the US, 2001-2007: a

medication exposure in pregnancy risk evaluation program study. *Paediatr Perinat Epidemiol*. 2012 Nov;26(6):578-88. doi: 10.1111/ppe.12004.

Borders-Hemphill V, Mosholder A. U.S. utilization patterns of influenza antiviral medications during the 2009 H1N1 influenza pandemic. *Influenza Other Respir Viruses*. 2012 Nov;6(6):e129-33. doi: 10.1111/j.1750-2659.2012.00384.x. Epub 2012 Jun 9.

Neyarapally GA, Hammad TA, Pinheiro SP, Iyasu S. Review of quality assessment tools for the evaluation of pharmacoepidemiological safety studies. *BMJ Open*. 2012 Sep 25;2(5). pii: e001362. doi: 10.1136/bmjopen-2012-001362.

Senior JR. Alanine aminotransferase: a clinical and regulatory tool for detecting liver injury-past, present, and future. *Clin Pharmacol Ther*. 2012 Sep;92(3):332-9.

Tu CM, Taylor K, Chai G. Use of proprietary names by prescribers for discontinued brand drug products when existing generic equivalents. *Pharmacoeconomics and Drug Safety*. Aug 2012

Chai G, Governale L, McMahon A, Trinidad J, Staffa J, Murphy D. Trends of Outpatient Prescription Drug Utilization in US Children, 2002-2010. *Pediatrics* 2012 Jul; 130(1):23-31.

Brajovic S., Piazza-Hepp T, Swartz L, Dal Pan G. Quality assessment of spontaneous triggered adverse event reports received by the Food and Drug Administration. *Pharmacoepidemiol Drug Saf*. 2012 Jun;21(6):565-70; Epub 2012 Feb 22.

Zhichkin PE, Athey BD, **Avigan MI**, Abernethy DR. Needs for an expanded ontology-based classification of adverse drug reactions and related mechanisms. *Clin Pharmacol Ther*. 2012 Jun;91(6):963-5.

Kim PW, **Sorbello AF, Wassel RT**, Pham TM, Tonning JM, Nambiar S. Eosinophilic pneumonia in patients treated with daptomycin: review of the literature and US FDA adverse event reporting system reports. *Drug Saf*. 2012 Jun 1;35(6):447-57.

Dal Pan GJ, Lindquist M, and **Gelperin K.** Postmarketing Spontaneous Pharmacovigilance Reporting Systems. In: Strom BL, Kimmel SE, Hennessy S, *Pharmacoepidemiology*, Fifth Edition. John Wiley and Sons, 2012.

Gatti, JC. The Importance of Physicians Identifying and Reporting Adverse Drug Events. *American Family Physician*, February 15, 2012, Vol 85, Number 4, p.318.

Beukelman T, Haynes K, Curtis JR, Xie F, Chen L, Bemrich-Stolz CJ, Delzell E, Saag KG, Solomon DH, Lewis JD et al. **Safety Assessment of Biological Therapeutics Collaboration.** Rates of malignancy associated with juvenile idiopathic arthritis and its treatment. *Arthritis Rheum*. 2012 Apr;64(4):1263-71. doi: 10.1002/art.34348.

Beukelman T, Xie F, Chen L, Baddley JW, Delzell E, Grijalva CG, Lewis JD, **Ouellet-Hellstrom R**, Patkar NM, Saag KG, Winthrop KL, and Curtis JR. Rates of Hospitalized Bacterial Infection Associated with Juvenile Idiopathic Arthritis and Its Treatment. *Arthritis & Rheumatism* 2012, 64 (8): 2773–2780, DOI 10.1002/art.34458.

Grijalva CG, Chen L, Delzell E, Baddley JW, Beukelman T, Winthrop KL, Griffin MR, Herrinton LJ, Liu L, **Ouellet-Hellstrom R**, Patkar NM, Solomon DH, Lewis JD, Xie F, Saag KG, Curtis JR. Initiation of tumor necrosis factor- α antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. *JAMA*. 2011 Dec 7;306(21):2331-9. doi: 10.1001/jama.2011.1692.

McMahon AW, Levenson MS, McEvoy BW, **Mosholder AD**, Murphy D. Age and risks of FDA-approved long-acting β_2 -adrenergic receptor agonists. *Pediatrics*. 2011 Nov;128(5):e1147-54. doi: 10.1542/peds.2010-1720. Epub 2011 Oct 24.

Herrinton LJ, Curtis JR, Chen L, Liu L, Delzell E, Lewis FD, Solomon DH, Griffin MR, **Ouellet-Hellstrom R**, Beukelman T, Grijalva CG, Haynes K, Duriya B, Lii J, Mitchel E, Patkar N, Rassen J, Winthrop KL, Nourjah P, and Saag KG. Study design for comprehensive assessment of biologic safety using multiple healthcare data systems. *Pharmacoepidemiol Drug Saf*. 2011 Nov;20(11):1199-209. doi: 10.1002/pds.2196. Epub 2011 Sep 15.

Dal Pan, GJ and Temple R. Invited Commentary—Balancing Transparency and Uncertainty: Comment on "Potential Safety Signals and Their Significance". *Arch Intern Med*. November 14, 2011. doi:10.1001/archinternmed.2011.546 (2011):20115461-2.

Hammad, T.A., Pinheiro, S.P., Neyarapally, G.A. Secondary use of randomized controlled trials to evaluate drug safety: a review of methodological considerations. *Clin Trials*. 2011 Oct;8(5):559-70. doi: 10.1177/1740774511419165. Epub 2011 Aug 30.

Kawai VK, Grijalva CG, Arbogast PG, Curtis JR, Solomon DH, Delzell E, Chen L, **Ouellet-Hellstrom R**, Herrington L, Liu L, Mitchell EF, Stein CM, and Griffin M. Changes in Co-therapies after Initiation of Disease-modifying Anti-rheumatic Drugs (DMARDs) Therapy in Patients with Rheumatoid Arthritis. *Arthritis Care Res (Hoboken)*. 2011 Oct;63(10):1415-24.

Senior JR, London WT, Sutnick AI. The Australia antigen and role of the late Philadelphia General Hospital in reducing post-transfusion hepatitis and sequelae. *Hepatology*. 2011 Sep 2;54(3):753-6

Nambiar S, Rellosa N, **Wassel RT, Borders-Hemphill V, Bradley JS**. Linezolid-associated peripheral and optic neuropathy in children. *Pediatrics*. 2011 Jun;127(6):e1528-32.

Manthripragada AD, **Zhou EH**, Budnitz DS, Lovegrove MC, Willy ME. Characterization of Acetaminophen Overdose-Related Emergency Department Visits and Hospitalizations in the United States. *Pharmacoepidemiol Drug Saf*. 2011 Aug;20(8):819-26. doi: 10.1002/pds.2090. Epub 2011 Feb 3.

2010

Hammad TA, Mosholder AD. Suicide and antidepressants. Beware extrapolation from ecological data. *BMJ*. 2010 Nov 30;341:c6844.

McMahon AW, Pratt RG, Hammad TA, Kozlowski S, Zhou EH, Lu S, Kullick CG, Mallick T, Dal Pan G. Description of hypersensitivity adverse events following administration of heparin that was potentially contaminated with OSCS in early 2008. *Pharmacoepidemiol Drug Saf*. 2010 Sep;19(9):921-33. doi: 10.1002/pds.1991.

Michele TM, **Pinheiro S, Iyasu S**. The safety of tiotropium – the FDA's conclusions. *NEJM* 2010 Sept 16; 363(12): 1097-9.

Diak P, Siegel J, La Grenade L, Choi L, Lemery S, McMahan A. Tumor necrosis factor alpha blockers and malignancy in children: forty-eight cases reported to the Food and Drug Administration. *Arthritis and rheumatism*. 2010 Aug; 62(8): 2517-24

Graham DJ, Ouellet-Hellstrom R, MaCurdy TE, Ali F, Sholley C, Worrall C, Kelman JA. Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. *JAMA*. 2010 Jul 28;304(4):411-8. Epub 2010 Jun 28.

Desai S, **Brinker A, Swann J, Iyasu S.** Sitagliptin-associated drug allergy: review of spontaneous adverse event reports. *Arch Intern Med*. 2010 Jul 12;170(13):1169-71. doi: 10.1001/archinternmed.2010.188.

Pamer CA, Hammad TA, Wu YT, Kaplan S, Rochester G, Governale L, Mosholder AD. Changes in US antidepressant and antipsychotic prescription patterns during a period of FDA actions. *Pharmacoepidemiol Drug Saf*. 2010 Feb; 19(2):158-74.

Senior JR. Unintended hepatic adverse events associated with cancer chemotherapy. *Toxicol Pathol*. 2010 Jan;38(1):142-7.